• Income Statement
• Balance Sheet
• Cash Flow
• Ratios
• Market Data
• Valuation

	ZyVersa Therapeutics, Inc. (ZVSA)
	Q4-CY2025	Q3-CY2025	Q2-CY2025	Q1-CY2025	Q4-CY2024	Q3-CY2024	Q2-CY2024	Q1-CY2024	Q4-CY2023	Q3-CY2023	Q2-CY2023	Q1-CY2023	Q4-CY2022	Q3-CY2022	Q2-CY2022	Q1-CY2022	Q4-CY2021	Q3-CY2021	Q2-CY2021	Q1-CY2021	Q4-CY2020	Q3-CY2020	Q2-CY2020	Q1-CY2020	Q4-CY2019	Q3-CY2019	Q2-CY2019	Q1-CY2019	Q4-CY2018	Q3-CY2018	Q2-CY2018	Q1-CY2018	Q4-CY2017	Q3-CY2017	Q2-CY2017	Q1-CY2017	Q4-CY2016	Q3-CY2016	Q2-CY2016	Q1-CY2016	Q4-CY2015	Q3-CY2015	Q2-CY2015	Q1-CY2015	Q4-CY2014	Q3-CY2014	Q2-CY2014	Q1-CY2014	Q4-CY2013
Balance Sheet Date		2025-Sep-30	2025-Jun-30	2025-Mar-31	2024-Dec-31	2024-Sep-30	2024-Jun-30	2024-Mar-31	2023-Dec-31
Fiscal Period		Q3-FY2025	Q2-FY2025	Q1-FY2025	Q4-FY2024	Q3-FY2024	Q2-FY2024	Q1-FY2024	Q4-FY2023
Total Assets		1,040,260$	19,641,111$	20,985,541$	20,599,414$	19,423,924$	19,469,504$	21,650,764$	22,114,284$				118,506,271$
Total Current Assets		995,533$	549,069$	2,110,310$	1,715,797$	390,415$	641,392$	2,900,052$	3,353,133$				6,362,546$
Cash and Cash Equivalents
Receivables
Other Current Assets
Assets Held for Sale in Short Term
Total Noncurrent Assets		44,727$	19,092,042$	18,875,231$	18,883,617$	19,033,509$	18,828,112$	18,750,712$	18,761,151$				112,143,725$
Goodwill											11,895,033$		11,895,033$
Other Intangible Assets
Physical Assets							1,733$	4,333$	6,933$				17,333$
Other Noncurrent Assets				18,647,903$	18,647,903$	18,647,903$	18,647,903$	18,647,903$	18,647,903$				100,086,329$
Assets Held for Sale in Long Term
Total Liabilities		12,765,827$	13,541,337$	12,855,191$	12,082,967$	12,396,624$	10,849,449$	10,427,630$	11,039,686$				18,511,943$
Total Current Liabilities		12,765,827$	12,689,678$	12,003,532$	11,231,308$	11,542,003$	9,994,828$	9,582,716$	10,194,772$				8,187,960$
Accounts Payable		9,805,129$	9,774,230$	9,604,568$	9,337,267$	9,284,631$	8,316,506$	8,127,746$	8,431,583$				6,025,645$
Short Term Debt
Short Term Capital Lease Obligations									8,656$				108,756$
Other Current Liabilities		681,296$	81,832$	111,831$	310,942$	163,269$	21,969$	51,969$	41,969$				214,229$
Total Noncurrent Liabilities		0$	851,659$	851,659$	851,659$	854,621$	854,621$	844,914$	844,914$				10,323,983$
Long Term Debt
Long Term Capital Lease Obligations
Other Noncurrent Liabilities
Total Equity		(11,725,567$)	6,099,774$	8,130,350$	8,516,447$	7,027,300$	8,620,055$	11,223,134$	11,074,598$	19,703,659$	20,061,642$	97,098,365$	99,662,997$
Equity to Minority
Equity to Common Shareholders		(11,725,567$)	6,099,774$	8,130,350$	8,516,447$	7,027,300$	8,620,055$	11,223,134$	11,074,598$	19,703,659$	20,061,642$	97,098,365$	99,662,997$
Additional Paid-In Capital		125,187,156$	123,207,260$	123,026,749$	121,155,922$	118,245,220$	117,436,743$	117,276,079$	114,300,849$				104,584,147$
Retained Earnings		(136,906,365$)	(117,100,806$)	(114,889,489$)	(112,632,559$)	(111,210,860$)	(108,809,604$)	(106,045,861$)	(103,219,124$)				(4,921,178$)
Treasury Stock		7,168$	7,168$	7,168$	7,168$	7,168$	7,168$	7,168$	7,168$
Capital Lease Obligations

Copy Table ✓